HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$112.45
+2.53%Sep 16, 2026, 20:30 UTC
Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033.
Sep 11, 2026, 11:58 UTC
Halozyme Therapeutics reported record second-quarter fiscal 2026 revenue of $481 million, up 48% year over year, with non-GAAP diluted EPS of $1.90, and raised its full-year 2026 guidance.
Source:Aug 22, 2026, 07:07 UTC
Allworth Financial LP acquired a new stake in Halozyme Therapeutics, Inc. during the second quarter, buying 37,664 shares valued at approximately $2,948,000.
Source:Aug 18, 2026, 00:00 UTC
Halozyme Therapeutics appointed Dannielle Appelhans as a director, effective August 14, 2026.
Aug 6, 2026, 22:21 UTC
Halozyme Therapeutics reported Q2 2026 earnings of $2.28 per share, surpassing the Zacks Consensus Estimate of $1.82 per share and up from $1.54 per share a year ago.
Aug 6, 2026, 07:07 UTC
Amundi acquired additional shares of Halozyme Therapeutics, increasing its stake by 503.5% during the quarter.
Source:Jul 21, 2026, 15:40 UTC
Halozyme Therapeutics grants Incyte Corporation rights to its ENHANZE drug delivery technology for developing subcutaneous formulations of cancer therapies.
Source:Jul 2, 2026, 00:00 UTC
Cortney Caudill will depart as Senior Vice President and Chief Operating Officer of Halozyme Therapeutics, Inc. effective June 30, 2026.